Fezolinetant Hot Flash Drug Linked to Tumor Risk: New Review
Fezolinetant’s Cancer-Safety Question Meets a New Dual-Blocker Rival in the Neurokinin Hot-Flash Race Meta-analyses of clinical trial data now show a co…
Evidence-based menopause and perimenopause research
Fezolinetant’s Cancer-Safety Question Meets a New Dual-Blocker Rival in the Neurokinin Hot-Flash Race Meta-analyses of clinical trial data now show a co…
Two reviews published in 2026 arrive at a shared conclusion: hormone therapy’s long-term safety depends less on the hormones themselves than on who take…
Nearly one in five Danish women over age 40 — 454,592 out of 2,350,335 tracked over 24 years — used systemic menopausal hormone therapy at least once
Across four Phase III trials involving women from very different backgrounds, the drug elinzanetant reduced moderate-to-severe hot flashes and night swe…
Surgical Menopause Outcomes: What the Evidence Says About Heart, Brain, and Long-Term Health A woman who has both ovaries removed before her natural men…
Menopause Brain Fog vs
Neuroimaging Reveals Brain Structure Changes After Early Menopause Premature or early menopause may set the stage for later cognitive issues by altering…
Earlier Menopause Age Linked to Accelerated Cognitive Decline and Brain Changes A 2026 study in JAMA Network Open provides direct structural evidence fo…
Introduction Menopause is more than a hormonal shift; it is a significant neuroendocrine transition that reconfigures a woman’s brain biology
Magnesium and Menopause: A Critical Mineral for Midlife Health The link between declining estrogen and bone health is well known